| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
1 company
J Matthew Singleton is Director at VKTX. J Matthew Singleton's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider; those holdings are worth an estimated $330K at current prices.
Our model assigns J Matthew Singleton a strong insider score of 75/100, based on 5 past trades. Over a 12-month horizon, all 5 of those trades were profitable, with an average 12-month return of +54.9%.
The VKTX filings lean toward selling, a net 59,286 shares.
J Matthew Singleton has 18 Form 4 filings on record from April 2015 to January 2026, all as Director at Viking Therapeutics (VKTX), 2015–2026.
The 30 reported transactions were 12 option or other derivative awards, 11 open-market sales, 5 option exercises and 1 stock award, plus smaller numbers of other types.
Counted by filing, the open-market trades come to 1 purchase worth about $93K and 5 sales worth about $4.6M.
The only open-market purchase was 9,500 shares of VKTX at an average $9.82 on May 31, 2018, about $93K.
The largest open-market sale was 16,000 shares of VKTX at an average $79.50 on October 25, 2024, about $1.3M. Twelve months later VKTX was down 56%.
All 5 sales since April 2023 were made under a Rule 10b5-1 trading plan, set up in advance.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Oct 25, 2024 | VKTX Viking Therapeutics, Inc. | Director | Sale+OE10b5-1 | 16,000 | $79.50 | $1,272,000.00 | -62.7% | -55.2% | -55.9% | |
| Sep 20, 2024 | VKTX Viking Therapeutics, Inc. | Director | Sale+OE10b5-1 | 10,300 | $69.50 | $715,850.00 | -52.0% | -41.1% | -64.0% | |
| Aug 21, 2024 | VKTX Viking Therapeutics, Inc. | Director | Sale+OE10b5-1 | 5,700 | $69.72 | $397,430.22 | -37.5% | -20.5% | -60.4% | |
| Aug 19, 2024 | VKTX Viking Therapeutics, Inc. | Director | Sale+OE10b5-1 | 16,000 | $62.22 | $995,453.24 | -62.7% | -26.3% | -63.4% | |
| Aug 14, 2024 | VKTX Viking Therapeutics, Inc. | Director | Sale+OE10b5-1 | 20,786 | $57.53 | $1,195,736.21 | -68.6% | +4.1% | -30.9% | |
| May 31, 2018 | VKTX Viking Therapeutics, Inc. | Director | Buy | 9,500 | $9.82 | $93,260.55 | New | - | - |